{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Adiponectin paradox",
      "Antagonistic pleiotropy",
      "COVID-19",
      "Diabetes mellitus",
      "Inflammation",
      "SARS-CoV-2"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33775925",
  "DateCompleted": {
    "Year": "2021",
    "Month": "09",
    "Day": "08"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "03",
        "Day": "26"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.drudis.2021.03.013",
      "S1359-6446(21)00149-5"
    ],
    "Journal": {
      "ISSN": "1878-5832",
      "JournalIssue": {
        "Volume": "26",
        "Issue": "8",
        "PubDate": {
          "Year": "2021",
          "Month": "Aug"
        }
      },
      "Title": "Drug discovery today",
      "ISOAbbreviation": "Drug Discov Today"
    },
    "ArticleTitle": "Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2.",
    "Pagination": {
      "StartPage": "2036",
      "EndPage": "2044",
      "MedlinePgn": "2036-2044"
    },
    "Abstract": {
      "AbstractText": [
        "Aging and pre-existing conditions in older patients increase severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) severity and its complications, although the causes remain unclear. Apart from acute pulmonary syndrome, Coronavirus 2019 (COVID-19) can increasingly induce chronic conditions. Importantly, SARS-CoV-2 triggers de novo type 2 diabetes mellitus (T2DM) linked to age-associated cardiovascular disease (CVD), cancers, and neurodegeneration. Mechanistically, SARS-CoV-2 induces inflammation, possibly through damage-associated molecular pattern (DAMP) signaling and 'cytokine storm,' causing insulin resistance and the adiponectin (APN) paradox, a phenomenon linking metabolic dysfunction to chronic disease. Accordingly, preventing the APN paradox by suppressing APN-related inflammatory signaling might prove beneficial. A better understanding could uncover novel therapies for SARS-CoV-2 and its chronic disorders."
      ],
      "CopyrightInformation": "Copyright \u00a9 2021 Elsevier Ltd. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "PCND Neuroscience Research Institute, Poway, CA, USA."
          }
        ],
        "LastName": "Ho",
        "ForeName": "Gilbert",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "PCND Neuroscience Research Institute, Poway, CA, USA."
          }
        ],
        "LastName": "Ali",
        "ForeName": "Alysha",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, Japan."
          }
        ],
        "LastName": "Takamatsu",
        "ForeName": "Yoshiki",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, Japan."
          }
        ],
        "LastName": "Wada",
        "ForeName": "Ryoko",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Neurosciences, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA."
          }
        ],
        "LastName": "Masliah",
        "ForeName": "Eliezer",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, Japan. Electronic address: hashimoto-mk@igakuken.or.jp."
          }
        ],
        "LastName": "Hashimoto",
        "ForeName": "Makoto",
        "Initials": "M"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Drug Discov Today",
    "NlmUniqueID": "9604391",
    "ISSNLinking": "1359-6446"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Adiponectin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Adiponectin"
    },
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "Aging"
    },
    {
      "QualifierName": [
        "immunology",
        "metabolism"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Chronic Disease"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Diabetes Mellitus, Type 2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Inflammation"
    },
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "Paracrine Communication"
    },
    {
      "QualifierName": [
        "pathogenicity",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    }
  ],
  "CoiStatement": "Declaration of interests The first author, Dr. Gilbert Ho, has previously served on an Advisory Board for Biogen, Inc. The remaining authors declare no known competing financial interests that might influence this paper."
}